QUEBEC, Sept. 11 /PRNewswire-FirstCall/ - Atrium Biotechnologies Inc. ("Atrium" or "the Company," TSX: ATB) is pleased to announce the acquisition, effective today, of the assets of London, Ontario based Douglas Laboratories Canada ("DL Canada"). DL Canada has been marketing Douglas Laboratories products in Canada since 2000 and has current annual revenues of approximately $5 million.
